Shield Therapeutics (LON:STX) Sets New 52-Week High – Still a Buy?

Posted by Teresa Graham on Jan 16th, 2026

Shield Therapeutics plc (LON:STX – Get Free Report) shares hit a new 52-week high during mid-day trading on Friday . The stock traded as high as GBX 12.50 and last traded at GBX 12.20, with a volume of 1258025 shares traded. The stock had previously closed at GBX 12.15.

Wall Street Analyst Weigh In

Separately, Peel Hunt reissued a “buy” rating and issued a GBX 15 price target on shares of Shield Therapeutics in a research note on Friday, November 7th. One research analyst has rated the stock with a Buy rating, According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of GBX 15.

Check Out Our Latest Research Report on STX

Shield Therapeutics Price Performance

The company has a quick ratio of 2.16, a current ratio of 1.05 and a debt-to-equity ratio of 3,691.50. The firm’s 50-day moving average is GBX 9.71 and its 200-day moving average is GBX 7.42. The company has a market cap of £129.54 million, a PE ratio of -6.10 and a beta of 1.42.

Shield Therapeutics Company Profile

(Get Free Report)

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.